Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Receivables - Net (2021 - 2025)

Historic Receivables - Net for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $259.0 million.

  • Indivior Pharmaceuticals' Receivables - Net rose 318.73% to $259.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.0 million, marking a year-over-year increase of 318.73%. This contributed to the annual value of $254.0 million for FY2024, which is 0.0% changed from last year.
  • Indivior Pharmaceuticals' Receivables - Net amounted to $259.0 million in Q3 2025, which was up 318.73% from $240.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year Receivables - Net high stood at $259.0 million for Q2 2024, and its period low was $202.0 million during Q4 2021.
  • Moreover, its 5-year median value for Receivables - Net was $247.0 million (2023), whereas its average is $242.1 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Receivables - Net surged by 1545.45% in 2023 and then crashed by 733.59% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Receivables - Net stood at $202.0 million in 2021, then increased by 8.91% to $220.0 million in 2022, then increased by 15.45% to $254.0 million in 2023, then changed by 0.0% to $254.0 million in 2024, then increased by 1.97% to $259.0 million in 2025.
  • Its last three reported values are $259.0 million in Q3 2025, $240.0 million for Q2 2025, and $243.0 million during Q1 2025.